PRESS RELEASE

Heidelberg Pharma Announces Presentation at H.C. Wainwright 23^rd Annual Global Investment Conference and Participation at Various Conferences

Ladenburg, Germany, 9 September 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences. Heidelberg Pharma uses Amanitin as an innovative toxin to develop new cancer therapies that, when coupled to an antibody, can specifically kill even dormant cancer cells and overcome resistance. The candidate HDP-101 is about to enter clinical development for the treatment of multiple myeloma.

H.C. Wainwright 23rd Annual Global Investment Conference (virtual format)
Dr. Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma, will give a corporate presentation at the virtual global investor conference. He and Prof. Dr. Andreas Pahl, CSO, will be available for 1 x 1 meetings, which can be arranged online via the conference system for 13^th, 14^th and 15^th September.
The presentation will be available online for registered attendees starting 13^th September 2021 at 7:00 am EDT / 1:00 pm CEST.

12th World ADC Congress (virtual format)
Prof. Dr. Andreas Pahl, CSO of Heidelberg Pharma, will hold a presentation on the unique mechanism of action of ATACs and the clinical candidate HDP-101 at the most important congress on Antibody Drug Conjugates.
Date: 11^th - 14^th October 2021
Presentation details:
Antibody Targeted Amanitin Conjugates (ATACs) Overcome Resistance Mechanisms to Establish New Treatment Options for Difficult to Treat Cancers.
Session: Looking at Novel & Outside of the Box Technologies
Date: 12^th October 2021 at 5:30 pm EDT / 11:30 pm CEST

BIO-Europe (virtual format)
Dr. George Badescu, VP Business Development and Dr. Artjom Wischnjow, Manager Business Development will be available for meetings at BIO-Europe, Europe's largest partnering conference. Appointments for 1 x 1 meetings can be made through partneringOne(R) platform.
Date: 25^th - 28^th October 2021

About Heidelberg Pharma's proprietary ATAC technology
Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates are ADCs which are based on the ATAC^(R) technology and whose payload consists of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma and will enter clinical development shortly. HDP-102, a CD37 ATAC for Non-Hodgkin's lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer, are in preclinical testing.

Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.